Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are
reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid …

Apixaban is a highly selective, reversible, direct factor Xa inhibitor that inhibits both free
factor Xa and prothrombinase activity, and clot-bound factor Xa activity. A predictable …

Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …

Apixaban (Eliquis™), an oral direct factor Xa inhibitor, is being developed by Bristol-Myers
Squibb and Pfizer as a therapy for the prevention and/or treatment of thrombotic disorders …

Objective: To provide a comprehensive review of the pharmacology, pharmacokinetics,
pharmacodynamics, clinical trial data, adverse effects, and drug interactions of apixaban …

Apixaban, an oral direct factor Xa inhibitor, is currently in late stage clinical development for
the prevention and treatment of thromboembolic diseases. In comparison with current …

For the last half-century, despite its many limitations warfarin has been the mainstay of
treatment for patients with venous and arterial thromboembolic disease. During the past …

Background Apixaban is an oral, selective, direct factor Xa inhibitor approved for
thromboprophylaxis after orthopedic surgery and stroke prevention in patients with atrial …

Apixaban is an oral, direct Factor Xa inhibitor that is being developed by Bristol-Myers
Squibb Co and Pfizer Inc. Apixaban is currently undergoing phase III clinical trials for …

Cardiovascular diseases are still the most important cause of morbidity and mortality
worldwide and anti-thrombotic treatment is widely used as a result. The currently used drugs …